Evidence map›Paper›PMID 31136659›Full record

Trial reportThe American journal of clinical nutrition2019

Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial.

Peter J Curtis, Vera van der Velpen, Lindsey Berends, Amy Jennings, Martin Feelisch, A Margot Umpleby, Mark Evans, Bernadette O Fernandez, Mia S Meiss, Magdalena Minnion and 5 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02035592 (The Effects of Blueberry Anthocyanins on Insulin Resistance and Vascular, Lung and Cognitive Function in a Population With Metabolic Syndrome.), which is not on this map. Cited by 127 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 14 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02035592 nacompletednot on this map

The Effects of Blueberry Anthocyanins on Insulin Resistance and Vascular, Lung and Cognitive Function in a Population With Metabolic Syndrome.

TypeinterventionalSponsorUniversity of East AngliaRan2014 to 2016Enrolled144ConditionsInsulin Resistance, Metabolic Syndrome XArmsFull dose blueberry, Half dose blueberry, Control
3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 14 syntheses or guidelines pooled it, 239 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Biomarkers of Berry Intake: Systematic Review Update.Journal of agricultural and food chemistry · 2023
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Peter J CurtisDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Vera van der VelpenDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Lindsey BerendsDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Amy JenningsDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Martin FeelischClinical and Experimental Sciences, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
A Margot UmplebyDepartment of Nutritional Sciences, University of Surrey, Guildford, United Kingdom.
Mark EvansWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
Bernadette O FernandezClinical and Experimental Sciences, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Mia S MeissClinical and Experimental Sciences, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Magdalena MinnionClinical and Experimental Sciences, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
John PotterDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Anne-Marie MinihaneDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Colin D KayDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Eric B RimmDepartments of Epidemiology & Nutrition, Harvard TH Chan School of Public Health, and Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Aedín CassidyDepartment of Nutrition & Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
University of East Anglia · GBUniversity Hospital Southampton NHS Foundation Trust · GBBrigham and Women's Hospital · USUniversity of Cambridge · GBUniversity of Surrey · GB

Funding

Biotechnology and Biological Sciences Research Council
6 · The paper itself

Abstract

backgroundAnthocyanin-rich blueberry intake is associated with reduced type 2 diabetes and cardiovascular disease (CVD) risk in prospective studies, although long-term randomized controlled trials (RCTs) have not been conducted in at-risk populations.

objectiveIn the longest-duration RCT to date, we examined the effect of 6-mo blueberry intake on insulin resistance and cardiometabolic function in metabolic syndrome.

methodsA double-blind, parallel RCT (n = 115; age 63 ± 7 y; 68% male; body mass index 31.2 ± 3.0 kg/m2) was conducted, which fed 2 dietarily achievable blueberry intakes [equivalent to 1/2 and 1 cup/d (75/150 g)] compared with matched placebo. Insulin resistance was assessed via the homeostasis model assessment of insulin resistance (primary endpoint) and confirmed by [6-6-2H2]-glucose-labeled, 2-step hyperinsulinemic clamp (n = 20). Clinically relevant cardiometabolic endpoints [including flow-mediated dilatation, augmentation index, lipoprotein status (by nuclear magnetic resonance spectroscopy), and nitric oxide (NO)-related metabolite assay] and anthocyanin metabolism were assessed.

resultsA daily intake of 1 cup of blueberries improved endothelial function (flow-mediated dilatation: +1.45%; 95% CI: 0.83%, 2.1%; P = 0.003), systemic arterial stiffness (augmentation index: -2.24%; 95% CI: -3.97%, -0.61%; P = 0.04) and attenuated cyclic guanosine monophosphate concentrations. In statin nonusers (n = 71), elevated high-density lipoprotein cholesterol (+0.08 mmol/L; P = 0.03), high-density lipoprotein particle density (+0.48n, ×10-6; P = 0.002) and apolipoprotein A-I (+0.05 g/L; P = 0.01) concentrations were observed following the 1-cup/d intervention. Treatment compliance was 94.1% (wrapper returns) and total concentrations of anthocyanin-derived phenolic acid metabolites significantly increased, dose-dependently, in serum and 24-h urine (P < 0.01 and P < 0.001, respectively). Insulin resistance, pulse wave velocity, blood pressure, NO, and overall plasma thiol status were unaffected. Likewise, a half cup per day had no effect on any biomarkers.

conclusionsDespite insulin resistance remaining unchanged we show, to our knowledge, the first sustained improvements in vascular function, lipid status, and underlying NO bioactivity following 1 cup blueberries/d. With effect sizes predictive of 12-15% reductions in CVD risk, blueberries should be included in dietary strategies to reduce individual and population CVD risk. This study was registered at clinicaltrials.gov as NCT02035592.

Indexed as

AgedApolipoproteinsBiomarkersBlood PressureBlueberry PlantsCholesterol, HDLCholesterol, LDLDouble-Blind MethodFemaleFruitHeartHumansInsulin ResistanceMaleMetabolic SyndromeMiddle AgedApolipoproteinsBiomarkersCholesterol, HDLCholesterol, LDLmetabolic syndrome, blueberry anthocyanins, flavonoids, cardiovascular disease risk, anthocyanin-derived phenolic acid metabolites

Identifiers

PMID31136659
PMCPMC6537945
OpenAlexW2935338472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.